Bassel Ericsoussi, MD
Critical Care Medicine · Munster, INNPI 1700087632
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.9% of the total across 57 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Johnson & Johnson at 42.7% of the total. Reporting peaked in 2024 at $444 and has fallen 59.8% since, to $178 in 2025.
Across 57 payments — averaging $31.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$777
- Pulmonx Corporation$241
- Intuitive Surgical$226
- GSK$129
- Grifols USA, LLC$88
- AMAG Pharmaceuticals, Inc.$87
- plus $271 from 5 others
What the payments were for
- Travel & lodging$1297%
- Food & beverage$1,69193%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 18 | $777 |
| Pulmonx Corporation | 2 | $241 |
| Intuitive Surgical | 2 | $226 |
| GSK | 14 | $129 |
| Grifols USA, LLC | 4 | $88 |
| AMAG Pharmaceuticals, Inc. | 1 | $87 |
| Boehringer Ingelheim | 4 | $80 |
| Mylan Specialty L.p. | 4 | $65 |
| AstraZeneca | 4 | $63 |
| Philips North America LLC | 2 | $40 |
| Genentech USA, Inc. | 2 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,819 in reported general payments places this provider in the 70th percentile of 158 critical care medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 21 | $212,999 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 153 | $108,572 |
| XolairOmalizumab | 28 | $96,947 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 99 | $57,649 |
| NucalaMepolizumab | 13 | $48,779 |
| Spiriva RespimatTiotropium Bromide | 63 | $45,740 |
| Breo ElliptaFluticasone/Vilanterol | 86 | $39,676 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 44 | $20,609 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $9,870 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $9,613 |
| Arnuity ElliptaFluticasone Furoate | 32 | $8,950 |
| Incruse ElliptaUmeclidinium Bromide | 27 | $8,592 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 211 | $5,835 |
| DalirespRoflumilast | 11 | $4,364 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 20 | $2,875 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $80 | $279,348128 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Nucala, Breo Ellipta, Arnuity Ellipta | $129 | $272,217410 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Daliresp | $63 | $23,84745 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 158 critical care medicine providers in Indiana.
Other critical care medicine in Munster
- Ibraheem YousefMunster$3K
- Carol BudginMunster$3K
- Virginia HylandMunster$2K
- Vrushank PatelIndianapolis$142K
- Matthew KoscielskiSouth Bend$118K
- Christopher KnieseIndianapolis$44K
- Stanley NasrawayIndianapolis$34K
- Ismail Al-AniSouth Bend$25K
- Horia DraghiciuRichmond$21K
- Shashikumar GowdaTerre Haute$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.